Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* A healthy male or female adult 18-45 years at the time of vaccination;~* Free of obvious health problems as established by medical history and physical examination before entering into the study;~* Written informed consent obtained from the subject;~* Able to read the Subject Information Sheet and Consent Form;~* Subjects who the investigator believes can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study;~* If the subject is female, she must be of non-childbearing potential, i.e. either surgically sterilized or one year post-menopausal; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions (i.e. intrauterine contraceptive device; oral contraceptives or other equivalent hormonal contraception, e.g. progestin implantable, cutaneous hormonal patch or injectable contraceptives) for 30 days prior to vaccination, have a negative pregnancy test within 48 hours prior to vaccination and must agree to continue such precautions for 60 days after completion of the vaccination series.~Exclusion Criteria:~* Pregnant or lactating female;~* Female planning to become pregnant or planning to discontinue abstinence or contraceptive precautions;~* History of any neurological or behavioral disorder or seizures, with the exception of a single febrile seizure in childhood;~* History of drug abuse or alcohol consumption (more than 2 drinks per day);~* History of allergic disease/reaction likely to be exacerbated by any component of the vaccine;~* History of urticaria related to mosquito bites requiring medical attention;~* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, renal, hematologic or endocrine functional defect, as determined by physical examination or laboratory tests;~* Any confirmed or suspected immunosuppressive or immunodeficient condition;~* Subject seropositive for HBsAg, anti-HCV or anti-HIV;~* Acute disease at the time of enrollment (acute disease is defined as the presence of a moderate or severe illness with or without fever);~* (Vaccine can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e., oral temperature \<37.5°C/\<99.5°F.)~* Chronic hepatomegaly, right upper quadrant abdominal pain or tenderness;~* Chronic splenomegaly, left upper quadrant abdominal pain or tenderness;~* Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the study vaccine (includes placebo) or planned use during the study period;~* Planned administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of the study vaccine and ending 30 days after;~* A planned move to a location that will prohibit participating in the trial for 9 months after the initial vaccination;~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 90 days preceding the first dose or planned administration during the study period. For corticosteroids, this will mean prednisone, or equivalent, 0.5 mg/kg/day. Inhaled and topical steroids are allowed;~* Administration of immunoglobulins and/or blood products within 90 days preceding the first dose or planned administration during the study period;~* Any chronic systemic drug therapy to be continued during the study period (except for vitamin/mineral supplements, a single anti-hypertension medication or routine treatment for gastro-esophageal reflux).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Pre-transfection F17 (Type: EXPERIMENTAL): 4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine
- Post-transfection F17 (Type: EXPERIMENTAL): 4 monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Lyophilized, single dose vials and sterile water for injection
- Post-transfection F19 (Type: EXPERIMENTAL): 4 monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Lyophilized, single dose vials and sterile water for injection
- Placebo (Type: PLACEBO_COMPARATOR): A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).